Navigation Links
MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271
Date:8/20/2013

ROCKVILLE, Md., Aug. 20, 2013 /PRNewswire/ -- MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, announced that the first patient has been dosed in a Phase 1 dose expansion cohort trial of MGA271.  MGA271 is an Fc-optimized monoclonal antibody that targets B7-H3, which is over-expressed on a wide variety of solid tumor types and is a member of the B7 family of molecules that are involved in immune regulation.  This milestone triggers a $10 million payment to MacroGenics from its partner, Les Laboratoires Servier, or Servier.

The dose expansion portion of this Phase 1 clinical trial of MGA271 is designed to further evaluate safety and pharmacokinetics at a weekly dose of 15 mg/kg.  The dose expansion portion of the trial also includes an early evaluation of the potential anti-tumor activity of MGA271.  MacroGenics plans to enroll 45 patients within three cohort groups: two with specific tumor types of 15 patients each, and a third cohort composed of other B7-H3-expressing tumor types.  MacroGenics is enrolling patients in the United States and expects to complete the Phase 1 trial in 2014.  Servier has indicated that it intends to evaluate MGA271 in 45 additional cancer patients representing additional tumor types beginning in the fourth quarter of 2013.

"MGA271 has significant potential to treat a variety of solid tumors and we are very pleased to reach this milestone in the product candidate's ongoing development," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.  "We intend to assess and prioritize future indications for MGA271 clinical trials based on data from these dose expansion cohorts and determine the best path forward to potential approval and commercialization."

In the dose escalation portion of the Phase 1 clinical trial, 26 patients were enrolled, representing 15 different types of tumors.  Ten patients received additional cycles of MGA271 treatment and all have had stable disease at the first tumor re-assessment.  The most frequent adverse events in the trial were mild or moderate infusion reactions.  No dose-limiting toxicity was observed. 

"Servier is very pleased to take this additional step in the development of MGA271," stated Stephane Depil, M.D., Ph.D., who leads Oncology Research & Development at Servier.  "We are encouraged by the initial potential for MGA271 in the treatment of a variety of B7-H3-expressing solid tumors." 

"Servier is committed to developing first-in-class, innovative drugs in oncology, such as MGA271, which may ultimately deliver an innovative treatment for cancer patients," said Dr. Emmanuel Canet, President of Research and Development at Servier.  "The various product candidates included in our two alliances with MacroGenics, including MGA271 and three oncology DART™ programs, are advancing as we had hoped."

Background on MGA271

MGA271 is a humanized, Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules which are involved in immune regulation, and is over-expressed on a wide variety of solid tumor types.  B7-H3 is over-expressed on differentiated tumor cells and cancer stem-like cells as well as on the supporting tumor vasculature and underlying tissues.  MGA271 is designed to destroy all of these components of the cancer in addition to reducing its inhibitory properties on T cells.

Servier MGA271 Collaboration

In November 2011, MacroGenics entered into a collaboration agreement with Servier.  Under this collaboration, MacroGenics granted Servier an option to obtain an exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India.  MacroGenics received a $20 million option grant fee up-front, will receive a $10 million milestone payment in the third quarter of 2013 in connection with the enrollment of the first patient in the Phase 1 dose expansion trial and may be eligible to receive up to an additional approximately $410 million in license grant fees, and clinical, development, regulatory and sales milestone payments.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases.  The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules.  The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines.  The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.   www.macrogenics.com

Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
2. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
3. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
4. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
5. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
6. Retired Pro Hockey Player 1st to Receive Total Artificial Heart in Upstate New York
7. Sensitech Inc. Products Receive Regulatory Compliance Approval from IATA
8. Nephros Receives 510(k) Clearance for Hemodiafiltration System
9. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
10. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
11. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
(Date:7/5/2017)... England , July 5, 2017 Wolfmet ... perfect answer as physics and manufacturing combine to progress molecular ... thyroid, existing SPECT systems are unable to accurately quantify the ... only limited information regarding the success of this radiotherapy treatment ... ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... Creative ... their partnership to provide the Pharmacist eCare Plan to Computer-Rx pharmacies ... country with the ability to develop the Pharmacist eCare Plan, a shared document ...
(Date:7/25/2017)... ... July 25, 2017 , ... Nautilus ... United States, today announced its partnership with financial technology company, Automated Transaction Delivery ... of the solution lies within Hyosung’s superior ATMs, assisted self-service devices and associated ...
(Date:7/25/2017)... , ... July 25, 2017 , ... SignatureCare Emergency Center ... the Austin, TX area 24 Hours a day. , The Emergency Room ... , “We’ve been open four months now and things are running smoothly,” said ...
(Date:7/24/2017)... ... ... SignatureCare Emergency Center is looking to award their 2017 Fall Scholarship. ... student. Get your applications in now as the deadline is approaching fast. ... a nursing student at Prairie View A&M University with a 3.45 GPA. Castillo was ...
(Date:7/24/2017)... ... July 24, 2017 , ... A four alarm ... construction site and threatened numerous homes and businesses nearby, causing some 700 individuals ... NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, Inc. notes that the ...
Breaking Medicine News(10 mins):